News

Eisai Limited is working with Health Canada on the approval of select products from the Eisai portfolio to be introduced in the Canadian market. Eisai said that in

In this newly created role, Mr Berger will be responsible for developing Catalent’s global marketing strategy, implementing marketing excellence across all business units as well as building Catalent’s

The current data suggest that VB-201 has anti-inflammatory properties that are active against psoriasis; an ongoing Phase 2 efficacy and safety study is currently evaluating VB-201 for the

Silodyx is a new compound indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) and recently approved by the European Medicines Agency (EMA).

The data are expected to be presented during a poster session at the 29th Annual Scientific Meeting of the American Pain Society (APS), and are supported by PriCara,

The double-blind, placebo-controlled clinical study was conducted by researchers at the University of Cincinnati – College of Medicine. The study, entitled ‘Improved cognitive-cerebral function in older adults with

IncellDx claimed that the HPV OncoTect E6, E7 mRNA test provides quantification of the over expression of E6/E7 mRNA in each cell, as well as the total proportion

Bayer HealthCare Pharmaceuticals claimed that Natazia is the first and only oral contraceptive that contains an estrogen called estradiol valerate and a progestin called dienogest. Estradiol valerate is

Bayer said that Regorafenib is a potent oral multi-kinase inhibitor with a kinase inhibition profile targeting angiogenic, stromal and oncogenic receptor tyrosine kinases. The Correct (Patients with metastatic